43 completed, 30 unknown, 9 terminated, 3 recruiting. 31 Phase 4, 24 Phase 3, 22 Phase 2, 9 Not applicable, 1 Phase 1.
Follow Simendan: new trials by email Literature Review of Simendan trials Research Report on Simendan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility Study AVATAR-SC, Levosimendan - Heart Failure | Not applicable | Recruiting | Niguarda Hospital | 60 | 2026-10-30 | 2026-10-13 |
| Levosimendan in Acute Decompensated Heart Failure Levosimendan, Standard care - Acute Decompensated Heart Failure (ADHF) | Phase 2 / Phase 3 | Not yet recruiting | Chittagong Medical College | 332 | 2025-12-01 | 2025-12-04 |
| Shorter Weaning From Invasive Ventilation With Levosimendan levosimendan, Soluvit, Standard care - Mechanical Ventilation, Weaning Failure | Phase 4 | Recruiting | Radboud University Medical Center | 250 | 2025-09-17 | 2026-01-09 |
| Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage Levosimendan, Placebo - Sub-arachnoid Haemorrhage | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2023-10-13 | 2026-08-31 |
| RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest Levosimendan Injection, physiological saline - Heart Arrest | Phase 4 | Unknown | Peking University Third Hospital | 60 | 2023-08-01 | 2023-07-21 |
| Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock Levosimendan 2.5 MG/ML Injectable Solution, Placebo - Cardiogenic Shock | Phase 3 | Recruiting | Pr Bruno LEVY | 610 | 2023-07-03 | 2025-08-05 |
| Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in Heart Failure Patients With Impaired Ejection Fraction Levosimendan, No Levosimendan - Levosimendan, Cardiac Surgery | Unknown | Central Hospital, Nancy, France | 300 | 2023-07-01 | 2023-09-01 | |
| Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV levosimendan, 5% glucose injection - Transesophageal Echocardiography, Acute Respiratory Distress Syndrome | Phase 2 / Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 58 | 2023-03-22 | 2023-03-14 |
| Efficacy and Clinical Outcomes of Levosimendan in E-CPR Levosimendan - Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication | Unknown | Hamad Medical Corporation | 100 | 2023-02-20 | 2023-02-16 | |
| Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction Levosimendan, PLACEBO - Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 230 | 2023-01-23 | 2023-05-15 |
| Impact of Levosimendan Preconditioning on Critical Care and In-hospital Lengths of Stay After Cardiac Surgery With Bypass Surgery Levosimendan - Levosimendan, Cardiac Surgery | Unknown | Central Hospital, Nancy, France | 120 | 2022-12-15 | 2023-01-17 | |
| Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome protective ventilation, prone position ventilation, glucocorticoid therapy - Acute Respiratory Distress Syndrome | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 1000 | 2022-10-01 | 2022-12-21 |
| Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function Levosimendan, Dobutamine, Milrinone - Acute Decompensated Heart Failure (ADHF), Cardiorenal Syndrome (CRS) | Phase 4 | Completed | Ain Shams University | 60 | 2022-06-01 | 2026-09-21 |
| Comparison Between Levosimendan and Adrenaline in CABG Patients Levosimendan, Adrenaline - Open Heart Surgery | Not applicable | Completed | Assiut University | 60 | 2022-03-25 | 2026-05-13 |
| Levosimendan In Ambulatory Heart Failure Patients Levosimendan, Placebo - Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV | Phase 4 | Terminated | Medical University of Bialystok | 70 | 2021-12-15 | 2025-05-09 |
| Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction Levosimendan, placebo - ST Elevation Myocardial Infarction, Heart Failure | Phase 4 | Unknown | Zhijun Sun | 500 | 2021-10-01 | 2021-08-20 |
| LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients Levosimendan, Placebo of Levosimendan - Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 206 | 2021-08-27 | 2025-03-21 |
| Levosimendan in Patients With Impaired Right Ventricular Function Undergoing Cardiac Surgery Levosimendan, Standard Care - Right Heart Failure, Open-heart Surgery | Phase 2 | Unknown | Ain Shams University | 40 | 2021-08-18 | 2021-10-20 |
| Levosimendan Versus Combination With Magnesium Sulphate on Spine Protection by NIRS in Infants Undergoing Coarctectomy Saline Solution, Levosimendan, Magnesium Sulfate - Aortic Coarctation | Phase 4 | Completed | Dalia Saad Abd-El Kader | 40 | 2021-02-04 | 2023-10-16 |
| Effect of Levosimendan on miRNAs Regulation in the Failing Hearts levosimendan - Heart Failure | Phase 4 | Unknown | Tongji Hospital | 136 | 2020-10-29 | 2021-07-16 |
Showing 20 of 89. Sign in to see all of them.
Heart Failure (29) · Cardiac Output, Low (8) · Shock, Cardiogenic (7) · Shock, Septic (5) · Aortic Valve Stenosis (4) · Cardio-Renal Syndrome (4) · Ventricular Dysfunction, Left (4) · Acute Kidney Injury (3) · Amyotrophic Lateral Sclerosis (3) · Cardiovascular Diseases (3) · Respiratory Distress Syndrome (3) · Sepsis (3) · Heart Defects, Congenital (2) · Heart Failure, Systolic (2) · Hip Fractures (2)
Orion Corporation, Orion Pharma (7) · Assistance Publique - Hôpitaux de Paris (4) · Tenax Therapeutics, Inc. (4) · Hospital Universitario de Canarias (3) · Sahlgrenska University Hospital (3) · University of Roma La Sapienza (3) · Abbott (2) · Ain Shams University (2) · Assiut University (2) · Central Hospital, Nancy, France (2) · Göteborg University (2) · Niguarda Hospital (2) · Tampere University Hospital (2) · University Medical Center Nijmegen (2) · Azienda Policlinico Umberto I (1)
Italy (12) · Sweden (11) · France (10) · Spain (10) · Finland (9) · United States (9) · Netherlands (7) · Austria (6) · China (6) · Egypt (6) · Germany (5) · Australia (4) · Canada (4) · Belgium (3) · Ireland (3)
Sven-Erik Ricksten, Professor (3) · Adelina Pellicer, PhD (1) · Albert Castellheim, MD, PhD (1) · Alberto Zangrillo, MD (1) · Amel HY Abelala, professor (1) · Anders Nydahl, Phd (1) · Andrea Morelli, M.D. (1) · Andrew Michaels, MD (1) · Anna Hofer, MD (1) · Ayse Baysal, MD (1) · Benjamin Glen Chousterman (1)
PMID 23620700, PMID 34536404, PMID 10093980, PMID 10889132, PMID 11069188, PMID 11748117, PMID 12947373, PMID 15023554, PMID 15329162, PMID 15475828, PMID 15519198, PMID 15769768, PMID 16181823, PMID 16461840, PMID 17086092, PMID 17331245, PMID 17377079, PMID 17473298, PMID 17566702, PMID 17855673, PMID 18279773, PMID 18297097, PMID 18359896, PMID 18405408, PMID 19054201, PMID 19114878, PMID 19151048, PMID 19426242, PMID 19539144, PMID 19700350, PMID 21182783, PMID 21258075, PMID 21546269, PMID 21784540, PMID 22004267, PMID 22429630, PMID 22440381, PMID 22459932, PMID 22480207, PMID 23063476, PMID 23288914, PMID 24126568, PMID 24464960, PMID 24614322, PMID 24621834, PMID 24920349, PMID 25390695, PMID 25734940, PMID 25837801, PMID 25989324
2019 (2), 2008 (1), 2009 (1)